Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance

Cardiovascular Lipid Risk Factors and Rate of Cardiovascular Events After Myocardial Revascularization

“…[18][19][20] Our study has some limitations. First, baseline characteristics of participants were defined in a relatively late stage of coronary artery disease, i.e.…”

Analysis of the Clinical Characteristics of Patients with Acute Coronary Syndrome in Different States of Renal Function

“…The guidelines of the United Kingdom's National Institute for Health and Care Excellence recommend the use of 20 mg atorvastatin for primary prevention and two grade prevention of CVD in patients with CKD. If non-HDL-C of patients declines to < 40% and eGFR ≥ 30 mL/min/1.73 m 2 , it is proposed that the dose of atorvastatin be increased (19). The "patient centered management of dyslipidaemia" released by the American National Lipid Association suggests that non-HDL-C is a more comprehensive related risk assessment index and a better primary target for treatment than LDL-C (20).…”

Statin-centric versus low-density lipoprotein-centric approach for atherosclerotic cardiovascular disease prevention: a Singapore perspective

“…While the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Treatment Guidelines (22) still use LDL-C levels to classify the degrees of risk for the primary prevention of ASCVD, the updated 2014 National Institute for Health and Care Excellence (NICE) guidelines recommend the use of non-high-density lipoprotein cholesterol (non-HDL-C), as it is a better predictor of risk than LDL-C. (23) Specifi cally, the NICE guidelines recommend the measurement of non-fasting lipid profi le, namely total cholesterol, HDL-C, non-HDL-C and triglycerides, before the initiation of lipid modifi cation therapy. Treatment recommendations are, however, based on statin intensity rather than LDL-C or non-HDL-C targets.…”

“…Treatment recommendations are, however, based on statin intensity rather than LDL-C or non-HDL-C targets. (23) When a target reduction of > 40% non-HDL-C is required, high-intensity statin therapy should be initiated. Although the defi nitions of low-, moderate-and high-intensity statin therapy are still based on estimations of LDL-C reduction, they differ slightly between the ACC/AHA and NICE guidelines (Table I).…”